IP Library › Granted Patent US 12,448,387
Granted Patent B2
US 12,448,387 · App. 18/659,338 · Granted Oct 21, 2025

Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yljimidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide

Inventors: Paul Allen Bethel (Cambridge, GB); Lai Chun Chan (Cambridge, GB); Katie Grace Cooper (Cambridge, GB); Robert John Cox (Cambridge, GB); Michael David Golden (Cambridge, GB); Shaun Alan Hughes (Cambridge, GB); Lucinda Victoria Jackson (Cambridge, GB); Kirsty Jane Millard (Cambridge, GB); Andrew John Phillips (Cambridge, GB); Alexander James Telford (Cambridge, GB); Jerry Evarts (Seattle, WA); Michael Joseph Lawler (Waunakee, WI); Remy E. J. N. Litjens (Weert, NL); Peter Johannes Servaas Savio Van Eijk (Weert, NL); Mathilda Maria Henrica Verstappen (Weert, NL); Frank L. M. Vos (Weert, NL); Eric Jurriën Zijp (Weert, NL); Qiu Junying (Tianjin, CN); Rustam Ferdinand Garrey (Salem, OR); David Allen Short (Springfield, OR); Angang Wang (Dalian, CN)
Assignee: Acerta Pharma B.V.
C07D487/04C07B63/00C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,448,387
App. No.
18/659,338
Granted
Oct 21, 2025
Kind
B2
Abstract

The present disclosure relates, in general, to improved processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)-benzamide, particularly large-scale processes for manufacturing 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide and intermediates used in such processes.

Claims (44)

1. A process for preparing a compound having the structure of Formula (VII):

or a salt thereof, wherein the process comprises:

contacting a compound having the structure of Formula (V):

or a salt thereof, with a compound having the structure of Formula (VI):

or a salt thereof, in the presence of a base and a palladium catalyst in an aqueous reaction medium comprising an organic solvent to form a reaction mixture comprising the compound of Formula (VII), or salt thereof;

decreasing the amount of water present in the reaction mixture to form a substantially anhydrous mixture comprising the compound of Formula (VII), or salt thereof; and

isolating the compound of Formula (VII), or salt thereof, from the substantially anhydrous mixture.

2. The process of claim 1 , wherein isolating comprises filtering the substantially anhydrous mixture.

3. The process of claim 1 , wherein the aqueous reaction medium further comprises an alkali metal halide.

4. The process of claim 1 , wherein the aqueous reaction medium further comprises potassium iodide.

5. The process of claim 1 , wherein the organic solvent comprises 2-butanol.

6. The process of claim 1 , wherein the base comprises at least one compound selected from the group consisting of triethylamine, potassium carbonate, potassium bicarbonate, sodium carbonate, sodium bicarbonate, cesium carbonate, tripropylamine, tributylamine, diiso-propylethylamine, N-methylmorpholine, N-methylpyrrolidine, methyldicyclohexylamine, and potassium phosphate.

7. The process of claim 1 , wherein the base comprises triethylamine.

8. The process of claim 1 , wherein the base comprises potassium carbonate.

9. The process of claim 1 , wherein the palladium catalyst comprises bis(tert-butyldicyclohexylphosphine)dichloropalladium(II).

10. The process of claim 1 , wherein the compound of Formula (VI) is contacted with about 0.5 to about 1.5 molar equivalents of the compound of Formula (V) relative to the compound of Formula (VI).

11. The process of claim 1 , wherein the aqueous reaction medium is maintained at a temperature from about 50° C. to about 100° C. during the contacting step.

12. The process of claim 1 , wherein the aqueous reaction medium has a volume ratio of water to organic solvent from about 1:3 to about 3:1.

13. The process of claim 1 , wherein decreasing comprises separating the reaction mixture into an aqueous discard phase and an organic phase comprising the compound of Formula (VII).

14. The process of claim 13 , wherein decreasing further comprises distilling the organic phase under conditions sufficient to decrease the amount of water present in the organic phase and provide the substantially anhydrous mixture; wherein the substantially anhydrous mixture comprises less than about 5 weight % water.

15. The process of claim 14 , wherein the organic phase is treated with a silica scavenger prior to distillation.

16. The process of claim 15 , wherein the silica scavenger comprises QuadraSil™ MP.

17. The process of claim 15 , wherein the process further comprises removing the silica scavenger from the organic phase prior to distillation.

18. The process of claim 15 , wherein decreasing comprises:

separating the reaction mixture into an aqueous discard phase and an organic phase comprising the compound of Formula (VII);

washing the organic phase with water;

treating the organic phase with a silica scavenger;

removing the silica scavenger from the organic phase;

washing the organic phase with an aqueous brine solution; and

distilling the organic phase under conditions sufficient to decrease the amount of water present in the organic phase.

19. The process of claim 14 , wherein the organic phase is distilled by vacuum distillation.

20. The process of claim 14 , wherein the organic phase is distilled at a temperature not exceeding about 60° C.

21. The process of claim 14 , wherein the organic phase comprises an alcohol.

22. The process of claim 21 , wherein during distilling the organic phase is supplemented with the alcohol.

23. The process of claim 21 , wherein the alcohol comprises 2-butanol.

24. The process of claim 1 , wherein the substantially anhydrous mixture comprises less than about 5 weight % water.

25. The process of claim 1 , wherein the substantially anhydrous mixture comprises less than about 3 weight % water.

26. The process of claim 1 , wherein isolating comprises crystallizing the compound of Formula (VII) from the substantially anhydrous mixture.

27. The process of claim 26 , wherein the substantially anhydrous mixture is maintained at a temperature of at least about 70° C. for a period of at least two hours after crystallization initiates.

28. The process of claim 26 , wherein the substantially anhydrous mixture is maintained at a temperature of at least about 70° C. for a period of at least two hours after crystallization initiates and then cooled to crystallize the compound of Formula (VII).

29. The process of claim 1 , wherein the compound of Formula (VII) isolated from the substantially anhydrous mixture comprises a crystalline form of the compound of Formula (VII) characterized by a reflection X-ray powder diffraction pattern comprising at least three peaks selected from the group consisting of 9.9±0.2°2θ, 11.1±0.2° 2θ, 12.8±0.2°2θ, 14.1±0.2°2θ, and 19.0±0.2°2θ.

30. The process of claim 1 , wherein the compound of Formula (VII) isolated from the substantially anhydrous mixture comprises a crystalline form of the compound of Formula (VII) characterized by a reflection X-ray powder diffraction pattern comprising at least three peaks selected from the group consisting of 7.4±0.2θ2θ, 11.7±0.2°2θ, 12.5±0.2°2θ, 12.5±0.2° 2θ, 22.3 0.2°2θ, and 21.6 0.2° 2θ.

31. The process of claim 1 , wherein the process further comprises converting the compound of Formula (VII), or salt thereof, to a compound having the structure of Formula (VIII):

or a salt thereof.

Assignments (14)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2024
From: W.R. GRACE & CO.-CONN.
To: ACERTA PHARMA B.V.
Reel/Frame 069043/0328 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2024
From: ASTRAZENECA UK LIMITED
To: ACERTA PHARMA B.V.
Reel/Frame 068687/0819 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2024
From: ACERTA PHARMA LLC
To: ACERTA PHARMA B.V.
Reel/Frame 068687/0838 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2024
From: ALCAMI CORPORATION
To: ACERTA PHARMA B.V.
Reel/Frame 068687/0912 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2024
From: ALCAMI CORPORATION
To: ACERTA PHARMA B.V.
Reel/Frame 068687/0919 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2024
From: KINGCHEM (LIAONING) CHEMICAL CO., LTD.
To: ACERTA PHARMA LLC
Reel/Frame 068687/0973 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2024
From: ASYMCHEM LIFE SCIENCE (TIANJIN) CO. LTD.
To: ACERTA PHARMA B.V.
Reel/Frame 068688/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2024
From: JUNYING, QIU
To: ASYMCHEM LIFE SCIENCE (TIANJIN) CO, LTD.
Reel/Frame 068677/0439 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2024
From: EVARTS, JERRY
To: ACERTA PHARMA LLC
Reel/Frame 068677/0512 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2024
From: LAWLER, MICHAEL JOSEPH
To: ALCAMI CORPORATION
Reel/Frame 068677/0809 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2024
From: VAN EIJK, PETER JOHANNES SERVAAS SAVIO; LITJENS, REMY E.J.N.; VERSTAPPEN, MATHILDA MARIA HENRICA; VOS, FRANK L.M.; ZIJP, ERIC JURRIËN
To: ALCAMI CORPORATION
Reel/Frame 068678/0027 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2024
From: BETHEL, PAUL ALLEN; CHAN, LAI CHUN; COOPER, KATIE GRACE; COX, ROBERT JOHN; GOLDEN, MICHAEL DAVID; HUGHES, SHAUN ALAN; JACKSON, LUCINDA VICTORIA; MILLARD, KIRSTY JANE; PHILLIPS, ANDREW JOHN; TELFORD, ALEXANDER JAMES
To: ASTRAZENECA UK LIMITED
Reel/Frame 068678/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2024
From: WANG, ANGANG
To: KINGCHEM (LIAONING) CHEMICAL CO., LTD.
Reel/Frame 069031/0411 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2024
From: GARREY, RUSTAM FERDINAND; SHORT, DAVID ALLEN
To: W.R. GRACE & CO.-CONN.
Reel/Frame 069032/0192 →
Continuity (3)
Division 17271750
Provisional Application 62724228 · Aug 29, 2018
Related Publication 20240317766A1 · Sep 26, 2024
References Cited (50)
US 7459554B2 · Dong et al. · 2008 [cited by applicant]
US 8362249B2 · Ginn et al. · 2013 [cited by applicant]
US 9290504B2 · Barf et al. · 2016 [cited by applicant]
US 9446130B2 · Kim et al. · 2016 [cited by applicant]
US 9463192B2 · Takeuchi et al. · 2016 [cited by applicant]
US 9487521B2 · Zhou et al. · 2016 [cited by applicant]
US 9512084B2 · Angst et al. · 2016 [cited by applicant]
US 10800787B2 · Bodhuri et al. · 2020 [cited by applicant]
US 11161851B2 · Wang et al. · 2021 [cited by applicant]
US 12024520B2 · Bethel et al. · 2024 [cited by applicant]
US 20140155385A1 · Barf et al. · 2014 [cited by applicant]
US 20190367524A1 · Cai et al. · 2019 [cited by applicant]
US 20190375755A1 · Sheng et al. · 2019 [cited by applicant]
US 20210395234A1 · Sakamoto et al. · 2021 [cited by applicant]
CN 103889987A · 2014 [cited by applicant]
CN 105683181A · 2016 [cited by applicant]
CN 107056786A · 2017 [cited by applicant]
CN 107522701A · 2017 [cited by applicant]
CN 108250186A · 2018 [cited by applicant]
JP 2014520870A · 2014 [cited by applicant]
JP 7439095B2 · 2024 [cited by applicant]
KR 20140036324A · 2014 [cited by applicant]
WO 2008121742A2 · 2008 [cited by applicant]
WO 2010126960A1 · 2010 [cited by applicant]
WO 2011095556A1 · 2011 [cited by applicant]
WO 2013010868A1 · 2013 [cited by applicant]
WO 2016128912A1 · 2016 [cited by applicant]
WO 2017002095A1 · 2017 [cited by applicant]
WO 2017077507A1 · 2017 [cited by applicant]
WO 2018115965A1 · 2018 [cited by applicant]
WO 2018116259A1 · 2018 [cited by applicant]
WO 2018130213A1 · 2018 [cited by applicant]
WO 2018191815A1 · 2018 [cited by applicant]
WO 2019090269A1 · 2019 [cited by applicant]
WO 2019239374A1 · 2019 [cited by applicant]
Anonymous, Use of I-bromo-3-[(2S)-pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-8-amine as an intermediate for making acalabrutinib, Research Disclosure database No. 631028, 2016, 2 Pages. [cited by applicant]
Ashton H., et al., “Thermal Stability of 2-Butynoic Acid (Tetrolic Acid)”, OPRD, 2019, 23, pp. 1101-1104. [cited by applicant]
Barf T., et al., “Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile,” Journal of Pharmacology and Experimental Therapeutics, US, Nov. 2017… [cited by applicant]
Bethel P.A., et al., “Development of Commercial Manufacturing Processes for Acalabrutinib”, OPRD, 2022, 26, pp. 3303-3311. [cited by applicant]
Caira M.R., “Crystalline Polymorphism of Organic Compounds”, Topics in Current Chemistry, Edited by E. Weber. Berlin: Springer, DE, 1998, vol. 198, Jan. 1, 1998, pp. 163-208, XP001156954, ISSN: 0340-1022, DOI: 10.1007/3… [cited by applicant]
Chen B., et al., “A Manufacturing Process to an Intermediate in the Synthesis of Acalabrutinib”, OPRD, 2018, 22, pp. 1458-1460. [cited by applicant]
Flick A.C., et al., “Synthetic Approaches to the New Drugs Approved During 2017”, J. Med. Chem. 62, 2019, pp. 7340-7382. [cited by applicant]
Inglesby P.A., et al., “Diethanolamine Boronic Esters: Development of a Simple and Standard Process for Boronic Ester Synthesis”, Organic Process Research Development 2020, 24, (9), pp. 1683-1689. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2019/072991, mailed Mar. 11, 2021, 11 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2019/072991, mailed Jan. 23, 2020, 15 Pages. [cited by applicant]
Liu H., et al., “Ibrutinib (Imbruvica): The First-in-Class Btk Inhibitor for Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia”, Innovative Drug Synthesis, Chap. 8, 1st Ed. 2016, pp… [cited by applicant]
Nankodo Co., Ltd., “Natural Products Chemistry for Pharmaceutical Students”, 2004, pp. 139-141, (Japanese textbook). [cited by applicant]
Zheng X., et al., “From Arylureas to Biarylamides to Aminoquinazolines: Discovery of a Novel, Potent TRPV1 Antagonist”, Bioorganic Medicinal Chemistry Letters vol. 16, 2006, pp. 5217-5221. [cited by applicant]
Brittain H.G., et al., “Polymorphism in Pharmaceutical Solids”, Drugs and the Pharmaceutical Sciences, vol. 192, Chapter 4, 2009, pp. 76-138. [cited by applicant]
Hirayama N., “Handbook of Organic Compound Crystal Preparation”, 2008, pp. 10-11, 57-73, 78-81. [cited by applicant]